L
Liminatus Pharma, Inc. (LIMN)
NGM – Real Time Price. Currency in USD
0.19
-0.01 (-6.59%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
0.19
-0.01 (-6.59%)
At close: May 12, 2026, 4:00 PM EDT
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
| Name | Position |
|---|---|
| Dr. Beom Kyu Choi | Chief Technology Officer & Member of Scientific Advisory Board |
| Dr. Byong Chul Yoo Ph.D. | Chief Science Officer & Member of Scientific Advisory Board |
| Dr. Sang-jin Lee Ph.D. | Head of Research & Development and Member of Scientific Advisory Board |
| Mr. Chris Kim J.D., L.L.M. | CEO & Chairman |
| Mr. Scott Dam | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-31 | 10-K | limn-20251231x10k.htm |
| 2026-03-04 | 8-K | tm267974d1_8k.htm |
| 2026-02-18 | 8-K | tm266571d1_8k.htm |
| 2026-02-11 | S-1 | limn-20250930xs1.htm |
| 2026-02-09 | 8-K | tm265593d1_8k.htm |
| 2026-01-26 | 8-K | tm264095d1_8k.htm |
| 2025-12-31 | DRS | filename1.htm |
| 2025-11-25 | 8-K | tm2532232d1_8k.htm |
| 2025-11-14 | 10-Q | limn-20250930x10q.htm |
| 2025-10-06 | 10-Q | limn-20250630x10q.htm |